4-year study shows Novo Nordisk's Wegovy maintains 10% weight loss in patients, suggesting sustained effects and potential for coverage.

Novo Nordisk's Wegovy obesity treatment maintained an average 10% weight loss for four years in patients, according to new data presented at the European Congress on Obesity. This long-term study could help convince insurers and governments to cover the cost of Wegovy, a costly yet effective drug. The research suggests that once significant weight loss is achieved, patients do not regain weight if they continue taking the medication.